Glutathione is a molecule made by the body from three amino acids. Cells use its reduced form, GSH, to transfer electrons in reactions that help handle peroxides and other reactive compounds. Studies of extra glutathione have produced different results depending on how it was given and what was measured: oral trials disagree about changes in blood and cellular stores, and an intranasal Parkinson trial did not outperform placebo.
Overview
GSH contains glutamate, cysteine and glycine. The glutamate–cysteine connection uses glutamate’s side-chain carboxyl group, giving the molecule its gamma-glutamyl name. Reduced glutathione and oxidized glutathione disulfide, GSSG, are related chemical forms with different assay meanings. A paper measuring total glutathione is therefore answering a different question from a paper measuring GSH alone or the GSH/GSSG ratio. PubChem identity record
Molecular profile
- Form
- Reduced L-glutathione (GSH), free molecule Source
- Sequence
- Gamma-L-glutamyl-L-cysteinyl-glycine; three residues Source
- Molecular formula
- C10H17N3O6S Source
- Molecular mass
- 307.33 g/mol, PubChem computed average molecular mass Source
- Reactive group
- Cysteine thiol; gamma-linked glutamate–cysteine bond Source
Forms and derivatives
Reduced GSH and oxidized GSSG
GSH is the reduced tripeptide. Oxidized glutathione, GSSG, contains two glutathione units linked through a disulfide. Studies that measure total glutathione, GSH alone or the GSH/GSSG ratio are measuring related but different quantities.
Oral, intravenous and intranasal preparations
Delivery method changes the sampled exposure and clinical question. An oral body-store result cannot establish the effect or safety of an injectable preparation, and an intranasal Parkinson trial cannot establish a general cognitive benefit.
This chemistry makes glutathione a genuine peptide, although its principal role here is an intracellular chemical participant rather than a receptor-selective peptide hormone. An explanation of its normal function should remain separate from a claim that a particular oral, nasal or intravenous product improves health.
Uses and research areas
Investigators have followed glutathione in plasma during the hours after administration, measured cellular stores after months of supplementation and tested symptoms in a defined patient population. Each approach examines a different step between giving a preparation and changing a person’s health. The oral studies below are especially useful for comparing the time scale and compartment of a biochemical response.
In Parkinson disease, early depletion of endogenous glutathione contributed to the rationale for testing augmentation. The intranasal phase IIb trial assessed whether treatment improved clinical symptoms relative to saline, making it possible to examine a patient outcome alongside the healthy-volunteer biomarker work. Mischley and colleagues, 2017
Mechanism of action
The enzyme glutathione peroxidase uses GSH to reduce peroxides. GSH supplies electrons and becomes oxidized to glutathione disulfide, GSSG, during the reaction. In Mills’s original red-blood-cell experiments, this glutathione-dependent activity helped protect hemoglobin against oxidative breakdown. The reaction explains why the amounts of reduced and oxidized glutathione are useful biochemical measurements. Mills, 1957
Reaction: 2 GSH + H₂O₂ → GSSG + 2 H₂O. The source experiment concerns erythrocyte biochemistry.
Glutathione peroxidase uses two reduced glutathione molecules, GSH, to reduce hydrogen peroxide to water. GSH becomes oxidized glutathione disulfide, GSSG: 2 GSH + H₂O₂ → GSSG + 2 H₂O. Mills’s red-blood-cell experiments linked glutathione-dependent activity to protection of hemoglobin against oxidative breakdown. The diagram shows this cellular reaction; the experiment did not test how much glutathione a supplement delivers to cells.
Mills GC. Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. Journal of Biological Chemistry. 1957;229(1):189–197. doi:10.1016/S0021-9258(18)70608-X.; National Center for Biotechnology Information. PubChem Compound Summary for CID 124886, Glutathione. Identity and computed-property record accessed October 14, 2026.
Supplying a molecule outside the cell adds absorption and distribution to that chemistry. Glutathione may be broken down, and its amino-acid components can affect subsequent synthesis. Aebi and colleagues’ infusion experiment found changes in cysteine as well as total glutathione. Those simultaneous changes make precursor availability relevant to interpreting what happens after an infusion. Aebi and colleagues, 1991
Pharmacokinetics
Witschi and colleagues followed seven healthy volunteers for 270 minutes after a single oral administration. Plasma glutathione, cysteine and glutamate did not increase significantly. This is evidence about acute systemic availability under those conditions. It does not measure how months of supplementation might alter cellular stores. Witschi and colleagues, 1992
In a separate intravenous experiment involving ten healthy volunteers, Aebi and colleagues reported a total-plasma-glutathione half-life of 14.1 ± 9.2 minutes (mean ± SD). The infusion also changed plasma cysteine and urinary excretion. The analyte was total plasma glutathione, and the preparation and route were specific to that experiment. It cannot establish nasal brain exposure or a universal duration of antioxidant activity. Original IV study
Acute plasma measurements and red-cell stores describe different compartments and time scales. Connecting either to a symptom change requires clinical measurements in the relevant population, as the Parkinson trial attempted below.
Research findings
Four weeks of oral supplementation did not improve the measured markers
Allen and Bradley enrolled 40 healthy adults in a randomized, double-blind, placebo-controlled trial; 39 completed the study per protocol. After four weeks, the oral glutathione group did not differ significantly from placebo in urinary F2-isoprostanes or 8-hydroxy-2′-deoxyguanosine, markers related to oxidative damage. Erythrocyte reduced and oxidized glutathione measures and their ratio were also unchanged. Allen and Bradley, 2011
A six-month trial found increased stores in several compartments
Richie and colleagues followed 54 nonsmoking adults in a six-month randomized trial of oral glutathione. In the higher-dose group, mean GSH concentrations at six months were about 30–35% above baseline in red blood cells, plasma and lymphocytes, a type of white blood cell. The increase was larger in cells sampled from the inner cheek. Most measurements moved back toward baseline during the month after supplementation stopped. These findings show that sustained oral supplementation can increase measured glutathione stores; the trial’s main outcomes were those concentrations. Richie and colleagues, 2015
The four-week and six-month studies differed in duration, measurements and study details. They did not directly compare the competing explanations for their contrasting results. The longer study establishes that measured stores can increase under its conditions; whether that biochemical change prevents illness or improves function requires additional clinical endpoints.
Intranasal Parkinson research did not establish superiority to placebo
Mischley and colleagues randomized 45 people with stage 1–3 Parkinson disease to saline or one of two doses of intranasal glutathione for three months, followed by a month without treatment. The higher-dose group improved from its own baseline on the total Unified Parkinson’s Disease Rating Scale and its motor subscore, but neither glutathione group improved more than the saline group. The investigators designed the trial to explore possible effects and did not give it the statistical power needed to establish superiority over placebo, leaving any symptomatic benefit uncertain. It also did not establish that glutathione slowed nerve-cell degeneration. Mischley and colleagues, 2017
Safety and tolerability
In the intranasal Parkinson trial, one participant in the higher active group withdrew after tachycardia and newly diagnosed cardiomyopathy. The report describes a cardiac history predating the study, leaving the relationship to glutathione unclear. This event matters when interpreting a small trial’s tolerability; the study cannot reliably estimate uncommon cardiac risks. Mischley and colleagues, safety results and discussion
Route and preparation quality affect safety. On August 27, 2026, FDA reported at least 30 patients with adverse events following compounded intravenous glutathione, alone or with other ingredients. Reported reactions included fever, chills, pain, dizziness and shock- or sepsis-like symptoms, with some hospitalizations. The investigation concerned supplement-grade starting material and excessive endotoxin, a bacterial component capable of causing serious inflammatory reactions. These are surveillance reports, not a controlled estimate of how frequently reactions occur. FDA communication
The presence of glutathione in the human body does not establish the suitability of a compounded injectable preparation. Oral and nasal studies likewise cannot establish IV product safety. No U.S. approval for the broad wellness, anti-ageing or Parkinson indications discussed here was identified in the reviewed evidence. The short trials also leave limited information about uncommon or long-term harms of particular delivery products.
What the research means
Glutathione supplies a useful example of the distance between established biochemistry and a clinical intervention. The redox system explains why investigators measure GSH, GSSG and oxidative-damage products. The intervention then needs to show that it reaches the relevant compartment and changes an outcome that matters to the intended population.
Current oral evidence supports the possibility of increasing some measured stores with longer supplementation, alongside an earlier negative controlled trial. The intranasal Parkinson result shows why baseline improvement alone cannot establish treatment efficacy. Those findings support a route- and endpoint-specific assessment, with particular attention to preparation quality for any injectable material.
FAQs
Is glutathione a peptide?
Yes. It contains three amino-acid residues, joined through an unusual gamma-glutamyl bond and a conventional peptide bond. Its cysteine thiol participates in redox chemistry; it is not a receptor-selective hormone simply because it is a peptide.
Can oral glutathione raise body stores?
A six-month randomized trial found higher GSH concentrations in red blood cells, plasma and several types of sampled cells. A four-week trial found no improvement in its glutathione or oxidative-damage measurements, and a single-dose experiment found no significant rise in plasma glutathione over 270 minutes. These studies examined different time periods and samples, so they do not tell us what proportion of every oral product is absorbed.
Does a higher GSH value prove better health?
A body-store measurement demonstrates a biochemical change in the sampled material. Demonstrating fewer symptoms, fewer complications or longer life requires those outcomes to be measured in controlled studies. The oral trials discussed here were largely designed around biomarkers.
Did intranasal glutathione improve Parkinson disease?
Neither intranasal glutathione group improved more than saline in the exploratory phase IIb trial. Participants in the higher-dose group improved from their own starting scores, but improvement also occurred with placebo. Because the study was not designed with enough participants to establish superiority, the size of any symptomatic benefit remains uncertain. The trial did not establish that treatment slowed the disease.
Why is injectable product quality a separate issue?
An endogenous molecule can be present in an unsuitable preparation. FDA’s August 2026 communication linked reported IV reactions with supplement-grade starting material and endotoxin concerns. Those reports concern preparation quality and route; they do not estimate the adverse-event rate of all glutathione products.
Comparisons and related reading
References
The references distinguish chemical identity, biochemical mechanism, human availability, controlled clinical outcomes and current safety surveillance. No supplement or infusion vendor serves as the scientific basis for an efficacy claim.
The identity record specifies reduced glutathione, its gamma-glutamyl linkage, formula and computed molecular mass. These fields do not describe glutathione disulfide or any delivery product.
The original erythrocyte work connects glutathione-dependent peroxide handling with protection of hemoglobin in an experimental system.
A single-administration experiment found no significant plasma rise over 270 minutes. Its acute plasma result has a different time scale and compartment from chronic supplementation studies.
Ten volunteers had a rapid rise and disappearance of total plasma glutathione with changes in cysteine and urinary excretion. The reported total-analyte half-life is specific to this IV experiment.
This four-week randomized study found no significant between-group change in its oxidative-damage markers or erythrocyte glutathione measures.
The six-month study found increases in several measured GSH compartments and return toward baseline after washout. Its principal endpoints were body stores, rather than prevention of disease.
The exploratory intranasal trial found within-group symptom change without superiority to saline. One higher-arm participant withdrew with tachycardia and newly diagnosed cardiomyopathy; prior cardiac history and uncertain causality matter to its safety assessment.
The current safety communication describes at least 30 reported adverse events after compounded IV preparations and contamination concerns linked to supplement-grade starting material.
Glossary
- Thiol
- A sulfur-containing –SH group that can participate in oxidation and reduction reactions.
- GSSG
- Glutathione disulfide, the oxidized form made from two linked glutathione molecules.
- Redox
- The transfer of electrons in oxidation and reduction reactions.
- Biomarker
- A measured biological characteristic; a change does not automatically establish a clinical benefit.
- Endotoxin
- A bacterial cell-wall component that can trigger severe inflammatory reactions when present in injectable products.